OSL Secures $5.6 million from Major Institutional Investors
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The funds will support the commercial launch of the OncoSil device in the United States and Australia following recent regulatory approvals. This financing strengthens the company's cash position, enhancing its path to commercialization and upcoming milestones in the first half of the fiscal year.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from OncoSil Medical
- Proposed issue of securities - OSL
- OncoSil submits US Reimbursement Application (Updated)
- OncoSil submits US Reimbursement Application
- Appendix 4G and Corporate Governance Statement
- Appendix 4E and Annual Report
Later from OncoSil Medical
- 100th Patient Treated with OncoSil device in Spain
- Australian Manufacturing Facility Achieves ISO 13485
- Application for quotation of securities - OSL
- Notice Under Section 708A
- Change in substantial shareholding for OSL
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical